DPH — Dechra Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapMomentum Trap

Annual income statement for Dechra Pharmaceuticals, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.

	2019 June 30th	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	482	515	608	682	762
Cost of Revenue
Gross Profit	278	292	346	385	430
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	444	465	521	600	777
Operating Profit	38	49.7	86.8	82	-15.1
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	27.8	40.9	74	77.6	-36.1
Provision for Income Taxes
Net Income After Taxes	20.9	33.9	55.5	58.2	-27.9
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	30.9	33.9	55.5	58.2	-27.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	30.9	33.9	55.5	58.2	-27.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.598	0.586	0.726	0.96	0.575
Dividends per Share